Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Comment by MyKnighton Jan 21, 2020 1:02pm
52 Views
Post# 30578384

RE:They will never have phase 3 finished by Jan next year

RE:They will never have phase 3 finished by Jan next yearAnd to be honnest I don't care.... money is coming in from EU that will be more then enough
  • Keep the company going with incredible revenu(100 Millions/year Min)
  • Pay for phase 3, FDA.
  • Continue research on all product including kal-1816
When you suffer and need an Bone narrow transplant where would you go for the next year if you can afford it.... Europe.

FDA is alway's the most expensive and the last one done.
Now getting Fast track and the orphean drug status, what more do you want as a sign from the FDA.

So 2020, getting operational with a market and money coming in.

Do your DD.

They will never have phase 3 finished by Jan next year

I’m not bashing ,realistic 
Bullboard Posts